Lucid Diagnostics Inc (LUCD) concluded trading on Thursday at a closing price of $1.25, with 7.83 million shares of worth about $9.78 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 56.00% during that period and on April 10, 2025 the price saw a loss of about -24.24%. Currently the company’s common shares owned by public are about 63.07M shares, out of which, 32.98M shares are available for trading.
Stock saw a price change of -16.67% in past 5 days and over the past one month there was a price change of -5.30%. Year-to-date (YTD), LUCD shares are showing a performance of 52.68% which increased to 35.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.63 but also hit the highest price of $1.80 during that period. The average intraday trading volume for Lucid Diagnostics Inc shares is 757.40K. The stock is currently trading -16.72% below its 20-day simple moving average (SMA20), while that difference is down -8.87% for SMA50 and it goes to 27.47% higher than SMA200.
Lucid Diagnostics Inc (NASDAQ: LUCD) currently have 63.07M outstanding shares and institutions hold larger chunk of about 5.20% of that.
The stock has a current market capitalization of $108.57M and its 3Y-monthly beta is at 1.20. It has posted earnings per share of -$1.07 in the same period. It has Quick Ratio of 1.03 while making debt-to-equity ratio of 3.94. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LUCD, volatility over the week remained 14.13% while standing at 9.57% over the month.
Stock’s fiscal year EPS is expected to rise by 29.75% while it is estimated to increase by 40.54% in next year. EPS is likely to grow at an annualized rate of 40.08% for next 5-years, compared to annual growth of -54.43% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ascendiant Capital Markets on December 27, 2021 offering a Buy rating for the stock and assigned a target price of $16 to it. Coverage by Needham stated Lucid Diagnostics Inc (LUCD) stock as a Buy in their note to investors on November 08, 2021, suggesting a price target of $17 for the stock. On November 08, 2021, Cantor Fitzgerald Initiated their recommendations, while on November 08, 2021, BTIG Research Initiated their ratings for the stock with a price target of $14.
